News Archive

MISSION Secures £20m ($32m) Series B Financing

MISSION Secures £20m ($32m) Series B Financing

Cambridge, UK – 18 November 2013 – MISSION Therapeutics Limited (MISSION), a biotechnology company developing novel inhibitors of deubiquitylating enzymes (DUBs) involved in the DNA damage response, announced that it has closed a Series B round of equity financing... LEARN MORE
Page 1 of 212